Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
From Iran to Israel: An Iranian volunteer’s unlikely stand in wartime - 2Which salad do you believe is a definitive group pleaser? Vote!
- 3Remote Headphones: Improve Your Sound Insight
- 4Foreign journalist kidnapped in Iraq: Interior Ministry
- 5What is ‘Auld Lang Syne’? Why we sing this song at midnight on New Year’s Eve.
- The Most Moving TED Talks You Want to Watch
- Vote in favor of your Favored Travel Movement
- The most effective method to Shake Hands Expertly: A Bit by bit Guide
- Instructions to Pick the Ideal SUV Size for Seniors
- Top 10 Moving Style Architects of the Year
- Council removes proposal to rename park named after former president of Israel
- All that You Really want to Be aware of Dental Inserts Facilities
- How AI fixed the James Webb Space Telescope's blurry vision
- Help Your Efficiency: 10 Authoritative Apparatuses to Attempt
